ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Parkinson's Disease
Interventions
DRUG

ADX48621

oral administration

DRUG

Placebo

oral administration

Trial Locations (25)

11725

Addex Investigator Site, Commack

33606

Addex Investigator Site, Tampa

33612

Addex Investigator Site, Boca Raton

35233

Addex Investigator Site, Birmingham

48034

Addex Investigator Site, Southfield

60612

Addex Investigator Site, Chicago

85013

Addex Investigator Site, Phoenix

90033

Addex Investigator Site, Los Angeles

92037

Addex Investigator Site, La Jolla

94085

Addex Investigator Site, Sunnyvale

97239

Addex Investigator Site, Portland

98034

Addex Investigator Site, Kirkland

06510

Addex Investigator Site, New Haven

Unknown

Addex Investigator Site, Innsbruck

Addex Investigator Site, Bordeaux

Addex Investigator Site, Clermont-Ferrand

Addex Investigator Site, Nantes

Addex Investigator Site, Paris

Addex Investigator Site, Toulouse

Addex Investigator Site, Bochum

Addex Investigator Site, Hanau

Addex Investigator Site, Hanover

Addex Investigator Site, Kassel

Addex Investigator Site, Marburg

Addex Investigator Site, Munich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Addex Pharma S.A.

INDUSTRY

NCT01336088 - ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter